Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | RARB | P10826 | 6/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RARA | P10276 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2453324 | 0.86 | CA2 (0.55) | CA2CYP4A11CYP4F2PPARAMEN1 | |
| SCHEMBL3535251 | 0.85 | CA2 (0.54) | CA2CYP4A11CYP4F2RARBPPARA | |
| SCHEMBL5108050 | 0.85 | L3MBTL1 (0.54) | CA2CYP4A11CYP4F2MEN1ALDH1A1 | |
| SCHEMBL27557738 | 0.85 | CA2 (0.53) | CA2CYP4A11CYP4F2 | |
| Hydrocinnamyl Alcohol SCHEMBL28034182 | 0.84 | POLB (0.59) | CA2CYP4A11MEN1ALDH1A1MAPT | |
| SCHEMBL8684163 | 0.80 | CYP4A11 (0.58) | CA2CYP4A11CYP4F2PPARA | |
| SCHEMBL1943907 | 0.80 | CA2 (0.67) | CA2CYP4A11 | |
| SCHEMBL8868256 | 0.79 | KDM4E (0.61) | CA2CYP4A11BACE1MEN1ALDH1A1 | |
| SCHEMBL11894717 | 0.79 | RARB (0.52) | CA2CYP4A11RARBMEN1ALDH1A1 | |
| SCHEMBL8947064 | 0.79 | RARB (0.61) | CA2CYP4A11RARBMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816385-B2 | Dimeric dicarboxylic acid derivatives, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-10-19 | — | — | US | disclosed |
| EP-1578716-A1 | DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS | NOVO NORDISK A/S (DK) | 2005-09-28 | — | — | EP | disclosed |
| US-20040259950-A1 | Novel compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2004-12-23 | — | — | US | disclosed |
| WO-2004056740-A1 | DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259950-A1 | Novel compounds, their preparation and use | PPARG, PPARA, PPARD | CA2 3175/4885CYP4A11 572/4885CYP4F2 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.